The clinical pattern is familiar to any primary care physician who has seen patients in the years following the COVID-19 pandemic. A previously healthy adult contracts a viral illness, recovers in the expected one to two weeks, and then experiences months of profound fatigue, exercise intolerance, racing heart on standing, brain fog, and difficulty regulating body temperature. The diagnostic label has shifted across decades—chronic fatigue syndrome, myalgic encephalomyelitis, post-Lyme syndrome, and now long COVID—but the underlying physiology shows striking convergence. Two mechanisms anchor most cases: autonomic nervous system dysregulation, often manifest as postural orthostatic tachycardia syndrome, and acquired mitochondrial dysfunction with impaired oxidative phosphorylation in skeletal muscle and central nervous system tissue.
The autonomic component is measurable. Tilt-table or even simple ten-minute standing tests demonstrate a heart rate rise of more than thirty beats per minute without a corresponding blood pressure drop in many post-viral patients. The pathophysiology appears to involve viral or autoimmune injury to small autonomic ganglia, reduced blood volume, and downregulated baroreflex sensitivity. The mitochondrial component is increasingly demonstrated by reduced oxygen consumption on cardiopulmonary exercise testing, abnormal muscle biopsy findings, and elevated lactate at low workloads. Inflammatory cytokine elevations and persistent viral antigen in some tissues appear to drive both processes. The result is a body that runs out of cellular energy quickly and struggles to keep blood flowing to the brain when standing.
Recovery follows a counterintuitive principle: aggressive rest in the early phase prevents the post-exertional crashes that otherwise extend the illness by weeks. Increasing fluid intake to three liters daily and sodium intake to eight to ten grams expands plasma volume and reduces tachycardia. Compression garments support venous return. Once stabilized, very gradual reconditioning—starting with recumbent or supine exercise, then seated, then upright over weeks—rebuilds cardiovascular tolerance without triggering relapse. Mitochondrial support with coenzyme Q10, magnesium, riboflavin, and an anti-inflammatory dietary pattern is reasonable adjunctive care. Sleep restoration is non-negotiable. Recovery is often measured in months rather than weeks, and patient understanding that the illness is biologically real, not psychogenic, is itself therapeutic.
References:
- Komaroff, A. L., & Lipkin, W. I. (2021). Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome. Trends in Molecular Medicine, 27(9), 895-906.
- Davis, H. E., Assaf, G. S., McCorkell, L., Wei, H., Low, R. J., Re’em, Y., et al. (2021). Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. eClinicalMedicine, 38, 101019.
- Vernino, S., Bourne, K. M., Stiles, L. E., Grubb, B. P., Fedorowski, A., Stewart, J. M., et al. (2021). Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting. Autonomic Neuroscience, 235, 102828.
Comments are closed